#United States #Clinical Trial #Pleasanton #Movano Health #Cuffless Device

Movano Health Launches Exciting Clinical Study

Movano Health, known for its innovative approach to wearable health technology, has officially launched a clinical trial for its new cuffless blood pressure monitoring device. This pivotal study comes on the heels of previous clinical trials conducted in the latter half of 2024, showcasing the company's commitment to enhancing health monitoring solutions.

Located in Pleasanton, California, Movano Health, a publicly traded company on Nasdaq (MOVE), is set to innovate the way blood pressure is measured with their advanced wrist-worn device. The aim of this latest trial is to assess the performance of its newly designed cuffless wearable against standard hospital-grade blood pressure devices, ensuring that accuracy and reliability are not compromised.

The current trial is projected to engage at least 70 participants, and it is expected to be concluded shortly within the first two weeks of February. Participants in the study will wear the cuffless device, which will monitor pulse pressure waveforms and also gather a range of additional vital health metrics. These include pulse rate, blood oxygen saturation (SpO2), respiration rate, and ECG waveforms, providing a comprehensive view of an individual's vital signs.

Michael Leabman, the Chief Technology Officer and Founder of Movano Health, shared insights on the new device, stating, "We have learned a great deal since our last clinical trial in November 2024, making significant improvements to our cuffless blood pressure wearable for enhanced data accuracy." He expressed excitement about the new design's potential, describing it as a major advancement in the effort to provide precise blood pressure monitoring without the traditional cuffs.

The February study builds upon a series of earlier trials conducted by Movano Health. In November 2024, June 2024, and October 2023, the company gathered vital data from over 60 participants of various backgrounds and health statuses, all of whom wore the Movano wrist device alongside established hospital-grade monitors. This method is crucial as it relies on both non-invasive data collection from the wearable as well as controlled comparisons to traditional methodologies.

Looking ahead, Movano Health plans to conduct an additional continuous blood pressure study in mid-2025, involving 100-150 participants. This large-scale study will utilize an arterial line to further fine-tune the underlying algorithms necessary for achieving FDA approval for their innovative device.

Founded in 2018, Movano Health has consistently pushed boundaries in the realm of healthcare technology with their flagship product, the Evie Ring. This device represents a new direction in wearable health technology, merging style with the capability of gathering medical-grade data. By leveraging modern, flexible designs, Movano Health continues to explore new ways to help individuals monitor their health proactively.

In their ongoing efforts to shape the future of health monitoring, Movano Health is dedicated to developing effective personalized health insights for diverse patient populations. For further details on Movano Health and their cutting-edge products, visit their official website at Movano.

As this clinical trial unfolds, it is evident that Movano Health is setting the stage for a transformative approach to continuous health monitoring, shedding traditional methods in favor of innovative solutions that promise to make personal health management easier and more accurate for everyone.